Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section
Launched by AIN SHAMS UNIVERSITY · Aug 15, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a higher dose of oxytocin, a medication that helps control bleeding, is more effective than the standard dose in preventing postpartum hemorrhage (excessive bleeding after childbirth) during elective cesarean sections in women who are at higher risk for complications. This research is important because controlling bleeding can significantly reduce serious health risks for mothers after delivery.
Women who may be eligible to participate in this trial are those who have certain medical conditions, such as high blood pressure or diabetes, a history of postpartum hemorrhage, or complications during pregnancy, like placenta previa or carrying twins. Participants can expect to receive either the standard or higher dose of oxytocin during their cesarean section, and they will be monitored for any bleeding issues in the first 24 hours after the surgery. It's essential to note that this study will not include women who have an allergy to oxytocin or those who have uncomplicated pregnancies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • - Medical disorders ie: Hypertensive diseases with pregnancy - Diabetes Mellitus - Collagen diseases - Coagulopathies - Cardiac diseases - Anemia
- • History of postpartum hemorrhage
- • Placental disorders ie: placenta previa
- • Infertility and ICSI
- • High Parity
- • History of Endometriosis
- • Fetal disorders (IUGR, IUFD, Preterm, Congenital anomalies, oligohydramnios or polyhydramnios, macrosomia)
- • Preterm labor on uterine relaxants
- • Twins pregnancy
- • Patients on antiplatelets and anticoagulants
- • Uneventful antenatal care
- Exclusion Criteria:
- • - Oxytocin Allergy
- • Normal uncomplicated pregnancy
- • Emergency cesarean section
- • Exhausted uterus due to trial of normal labor
- • Couvelaire uterus
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported